AI Article Synopsis
- Systemic mast cell activation disease (MCAD) affects 5-10% of the population and leads to widespread symptoms from overactive mast cells, posing challenges during surgical procedures.
- Findings from literature and expert consensus provide guidelines for effectively treating MCAD patients undergoing invasive procedures.
- By recognizing and addressing specific MCAD considerations during surgery and anesthesia, healthcare providers can avoid unnecessary risk classification for these patients.
Article Abstract
Background: Systemic mast cell activation disease (MCAD, prevalence 5-10%) is a multifactorial, polygenic disease with multisystemic symptoms that is characterized by an unregulated increased release of mast cell mediators and an accumulation of activated mast cells potentially in all organs and tissues. Due to the high prevalence of the disease, physicians involved in surgical, anesthesiological and interventional procedures are often unknowingly faced with MCAD patients experiencing unexpected preoperative, intraoperative and postoperative complications, if no mast cell-specific treatment regimens have been applied.
Objective: The findings from a literature search, consensus recommendations of the various international expert groups and extensive own experience in the treatment of MCAD patients enable an empirical and evidence-based care of MCAD patients in association with invasive procedures.
Results And Conclusion: Due to the high prevalence of MCAD in the population, it can be assumed that patients with MCAD are correspondingly frequently represented in the surgical patient collective. When MCAD-specific peculiarities are preventively considered in the anesthesiological and surgical procedures in patients with proven or suspected mast cell disease, MCAD patients should not be classified as being at risk.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00104-019-0935-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of Earthworm () extract on atopic dermatitis: An in vitro and in vivo study.
Heliyon
January 2025
KM Science Research Division, Korea Institute of Oriental Medicine, 1672 Yuseongdae-ro, Yuseong-gu, Daejeon, 34054, South Korea.
Earthworm () is used as a traditional medicine for the management of allergic airway inflammation. Atopic dermatitis (AD) is a persistent, recurrent disorder marked by allergic inflammation and skin barrier dysfunction. However, the pharmaceutical effects of earthworms on AD have not been defined.
View Article and Find Full Text PDFCulprit allergen prevalence in polyreactive individuals reflects prescription trends: A tool for estimating comparative anaphylaxis risk using the example of neuromuscular blocking agents.
Anaesth Intensive Care
January 2025
Department of Anaesthesia, Sir Charles Gairdner Hospital, Nedlands, Australia.
Prescription-event monitoring (PEM) is the current gold standard for determining the risk of rare drug side-effects and comparing the risk between agents; however, spontaneous or prompted reporting schemes have low case-detection rates and exposure may be difficult to estimate. A novel method is described that allows a comparative adverse event rate between two drugs to be estimated-based on patterns of cross-reactivity-requiring only a sample of cases and no direct knowledge of drug exposure rates. Agreement was compared between the novel method and historical estimates of risk using PEM for comparative risk of rocuronium versus vecuronium anaphylaxis.
View Article and Find Full Text PDFThe present study aimed to evaluate the histologic, histochemical, and immunohistochemical changes in buffalo livers with cystic echinococcosis. Noninfected and infected livers were collected from the freshly slaughtered buffalo at the Aligarh abattoir. Small pieces of both infected and noninfected livers ( = 5) were cut and processed for histologic and histochemical studies.
View Article and Find Full Text PDFQuantum molecular resonance ameliorates atopic dermatitis through suppression of IL36G and SPRR2B.
BMB Rep
January 2025
Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea; Department of Medical Sciences, Graduate School, The Catholic University of Korea, Seoul 06591, Korea; Institute for Aging and Metabolic Diseases, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
Atopic dermatitis (AD) is a chronic, pruritic skin disease characterized by inflammation and skin lesion cornification. While the use of corticosteroids like dexamethasone (DXM), an antiinflammatory drug, improves symptoms temporarily and quickly, this use is not a cure. Thus, we aimed to identify a new therapeutic strategy for AD using quantum molecular resonance (QMR), a novel non-invasive technique with an electromagnetic field-based therapeutic approach as an alternative to pain killers.
View Article and Find Full Text PDF[Mechanisms of allergen-specific immunotherapy].
Nihon Yakurigaku Zasshi
January 2025
Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development.
Allergen-specific immunotherapy (AIT) has been a longstanding treatment for allergic diseases. Historically, subcutaneous immunotherapy was the main approach, but with the development of sublingual preparations, which are associated with fewer systemic side effects, sublingual immunotherapy is gaining global popularity. In Japan, the approval of standardized sublingual immunotherapy preparations in 2014 has significantly accelerated its adoption.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!